News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Andromeda Announces FDA Orphan Drug Designation for DiaPep277 for the Treatment of Type 1 Diabetes With Residual Beta Cell Function



5/28/2012 11:11:13 PM

YAVNE, Israel, May 28, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the US Food and Drug Administration (FDA) granted Orphan Drug designation for DiaPep277(R) for the treatment of type 1 diabetes (T1D) patients with residual beta cell function.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES